Global Information
회사소개 | 문의 | 비교리스트

세계의 보균자 검사 시장(2021-2031년) : 유형, 제품, 보균자 검사 유형, 기술, 적응증, 지역별

Carrier Screening Market - A Global and Regional Analysis: Focus on Type, Product, Carrier Screening Type, Technology, Indication, and Region - Analysis and Forecast, 2021-2031

리서치사 BIS Research Inc.
발행일 2021년 12월 상품코드 1044193
페이지 정보 영문 배송안내 1-2일 (영업일 기준)
가격
US $ 5,250 ₩ 6,689,000 PDF (1-3 User License)
US $ 8,100 ₩ 10,321,000 PDF and Excel (Global License)


세계의 보균자 검사 시장(2021-2031년) : 유형, 제품, 보균자 검사 유형, 기술, 적응증, 지역별 Carrier Screening Market - A Global and Regional Analysis: Focus on Type, Product, Carrier Screening Type, Technology, Indication, and Region - Analysis and Forecast, 2021-2031
발행일 : 2021년 12월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 보균자 검사 시장 규모는 2020년 11억 8,740만 달러에서 예측기간 중 12.67%의 연평균 복합 성장률(CAGR)로 성장을 지속하여 2031년에는 44억 7,900만 달러 규모로 성장할 것으로 예측됩니다.

보균자 검사 시장의 성장은 시퀀스 비용 하락, 복잡한 유전자 질환의 조기 발견과 예방의 중요성 증가, 임신 합병증으로 이어지는 모체 연령 상승 등에 의해 초래될 것으로 예상됩니다. 한편, 규제상 과제, 검사 센터 부족 등의 시장 성장을 억제하는 큰 과제가 있습니다.

세계의 보균자 검사(Carrier Screening) 시장을 조사했으며, 시장 개요, 코로나19(COVID-19) 및 기타 시장 영향요인 분석, 법규제 및 상환 환경, 시장 규모 추이와 예측, 유형·제품·보균자 검사 유형·기술·적응증·지역/주요 국가 등 각종 구분별 분석, 경쟁 환경, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 시장

제2장 산업 분석

  • 개요
  • 미국의 법적 요건과 프레임워크
  • 유럽의 법적 요건과 프레임워크
  • 아시아태평양의 법적 요건과 프레임워크
  • 상환 분석

제3장 시장 역학

  • 개요
  • 영향 분석
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회

제4장 경쟁 구도

  • 개요
  • 제품 발매
  • 시너지 효과가 있는 활동
  • 인수
  • 제품 승인 및 자금 제공
  • 시장 점유율 분석
  • 성장 점유율 분석

제5장 유형별 예측

  • 개요
  • 확장형 보균자 검사
    • 맞춤형 패널 테스트
    • 사전 설계형 패널 테스트
  • 표적 보균자 검사

제6장 제품별 예측

  • 개요
  • In Vitro Diagnostics (IVD)
  • Laboratory Developed Tests (LDT)

제7장 보균자 검사 유형별 예측

  • 개요
  • 산전 보균자 검사
    • IVD
    • LDT
  • 임신전 보균자 검사
    • IVD
    • LDT

제8장 기술별 예측

  • 개요
  • 차세대 시퀀싱(NGS)
  • 중합효소 연쇄반응(PCR)
    • 실시간 중합효소 연쇄반응(RT-PCR)
    • 디지털 PCR(dPCR)
  • 마이크로어레이
  • 기타

제9장 적응증별 예측

  • 개요
  • 취약X증후군
  • 낭포성 섬유증
  • 척수성 근위축
  • 다운증후군
  • 지중해빈혈
  • 테이삭스병
  • 헌팅턴병
  • 겸상 적혈구 빈혈
  • 혈우병
  • 기타

제10장 지역별 예측

  • 개요
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 기타 지역

제11장 기업 개요

  • BGI Group
  • CENTOGENE N.V.
  • Eurofins Scientific
  • Fulgent Genetics, Inc.
  • Gene by Gene, Ltd.
  • Illumina, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • OPKO Health
  • Quest Diagnostics Incorporated
  • Sema4
  • Thermo Fisher Scientific Inc.
  • Yourgene Health Plc
LSH 22.01.20

List of Figures

  • Figure 1: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
  • Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Carrier Screening Market
  • Figure 3: Global Carrier Screening Market (by Type), $Million, 2020 and 2031
  • Figure 4: Global Carrier Screening Market (by Product), $Million, 2020 and 2031
  • Figure 5: Global Carrier Screening Market (by Technology), $Million, 2020 and 2031
  • Figure 6: Global Carrier Screening Market (by Indication), $Million, 2020 and 2031
  • Figure 7: Global Carrier Screening Market (by Carrier Screening Type), $Million, 2020 and 2031
  • Figure 8: Global Carrier Screening Market Snapshot
  • Figure 9: Global Carrier Screening Market: Segmentation
  • Figure 10: Global Carrier Screening Market: Methodology
  • Figure 11: Primary Research Methodology
  • Figure 12: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 13: Top-Down Approach (Segment-Wise Analysis)
  • Figure 14: Global Carrier Screening Market, $Million, 2020-2031
  • Figure 15: Global Carrier Screening Market: COVID-19 Impact Analysis
  • Figure 16: Europe In Vitro Diagnostic Devices Regulation Regulatory Process
  • Figure 17: China NMPA Regulatory Approval Process
  • Figure 18: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
  • Figure 19: Share of Key Developments and Strategies, January 2018-December 2021
  • Figure 20: Number of Product Launches (by Company), January 2018-December 2021
  • Figure 21: Share of Synergistic Activities (by Company), January 2018-December 2021
  • Figure 22: Share of Acquisitions (by Company), January 2018-November 2021
  • Figure 23: Share of Product Approvals and Fundings (by Company), January 2018-November 2021
  • Figure 24: Market Share Analysis for Global Carrier Screening Market, $Million, 2019 and 2020
  • Figure 25: Growth Share Analysis for Global Carrier Screening Market (by Company), 2020
  • Figure 26: Global Carrier Screening Market (by Type)
  • Figure 27: Global Carrier Screening Market (by Type), $Million, 2020 and 2031
  • Figure 28: Global Carrier Screening Market (Expanded Carrier Screening), $Million, 2020-2031
  • Figure 29: Global Carrier Screening Market (Customized Panel Testing), $Million, 2020-2031
  • Figure 30: Global Carrier Screening Market (Predesigned Panel Testing), $Million, 2020-2031
  • Figure 31: Global Carrier Screening Market (Targeted Carrier Screening), $Million, 2020-2031
  • Figure 32: Global Carrier Screening Market (by Product)
  • Figure 33: Global Carrier Screening Market (by Product), $Million, 2020 and 2031
  • Figure 34: Global Carrier Screening Market (IVD), $Million, 2020-2031
  • Figure 35: Global Carrier Screening Market (Laboratory Developed Tests (LDT)), $Million, 2020-2031
  • Figure 36: Global Carrier Screening Market (by Carrier Screening type)
  • Figure 37: Global Carrier Screening Market (by Type), $Million, 2020 and 2031
  • Figure 38: Global Carrier Screening Market (Prenatal Carrier Screening), $Million, 2020-2031
  • Figure 39: Global Carrier Screening Market (Prenatal Carrier Screening (IVDs)), $Million, 2020-2031
  • Figure 40: Global Carrier Screening Market (Prenatal Carrier Screening,(LDTs)), $Million, 2020-2031
  • Figure 41: Global Carrier Screening Market (Preconception Carrier Screening), $Million, 2020-2031
  • Figure 42: Global Carrier Screening Market (Preconception Carrier Screening (IVDs)), $Million, 2020-2031
  • Figure 43: Global Carrier Screening Market (Preconception Carrier Screening (LDTs)), $Million, 2020-2031
  • Figure 44: Global Carrier Screening Market (by Technology)
  • Figure 45: Global Carrier Screening Market (by Technology), $Million, 2020 and 2031
  • Figure 46: Global Carrier Screening Market (Next-Generation Sequencing), $Million, 2020-2031
  • Figure 47: Global Carrier Screening Market (Polymerase Chain Reaction), $Million, 2020-2031
  • Figure 48: Global Carrier Screening Market (Polymerase Chain Reaction), $Million, 2020 and 2031
  • Figure 49: Global Carrier Screening Market (RT-PCR), $Million, 2020-2031
  • Figure 50: Global Carrier Screening Market (dPCR), $Million, 2020-2031
  • Figure 51: Global Carrier Screening Market (Microarray), $Million, 2020-2031
  • Figure 52: Global Carrier Screening Market (Other Technologies), $Million, 2020-2031
  • Figure 53: Global Carrier Screening Market (by Indication)
  • Figure 54: Global Carrier Screening Market (by Indication), $Million, 2020 and 2031
  • Figure 55: Global Carrier Screening Market (Fragile X Syndrome), $Million, 2020-2031
  • Figure 56: Global Carrier Screening Market (Cystic Fibrosis), $Million, 2020-2031
  • Figure 57: Global Carrier Screening Market (Spinal Muscular Atrophy), $Million, 2020-2031
  • Figure 58: Global Carrier Screening Market (Down's Syndrome), $Million, 2020-2031
  • Figure 59: Global Carrier Screening Market (Thalassemia), $Million, 2020-2031
  • Figure 60: Global Carrier Screening Market (Tay-Sachs Disease), $Million, 2020-2031
  • Figure 61: Global Carrier Screening Market (Huntington's Disease), $Million, 2020-2031
  • Figure 62: Global Carrier Screening Market (Sickle Cell Anemia), $Million, 2020-2031
  • Figure 63: Global Carrier Screening Market (Hemophilia), $Million, 2020-2031
  • Figure 64: Global Carrier Screening Market (Other Indication), $Million, 2020-2031
  • Figure 65: Global Carrier Screening (by Region): Market Snapshot
  • Figure 66: Global Carrier Screening Market (by Region), $Million, 2020-2031
  • Figure 67: Global Carrier Screening Market (by Region), $Million, 2020 and 2031
  • Figure 68: North America Carrier Screening Market, $Million, 2020-2031
  • Figure 69: North America Carrier Screening Market (by Country), $Million, 2020-2031
  • Figure 70: U.S. Carrier Screening Market, $Million, 2020-2031
  • Figure 71: Canada Carrier Screening Market, $Million, 2020-2031
  • Figure 72: Europe Carrier Screening Market, $Million, 2020-2031
  • Figure 73: Europe Carrier Screening Market (by Country), $Million, 2020-2031
  • Figure 74: Germany Carrier Screening Market, $Million, 2020-2031
  • Figure 75: France Carrier Screening Market, $Million, 2020-2031
  • Figure 76: U.K. Carrier Screening Market, $Million, 2020-2031
  • Figure 77: Italy Carrier Screening Market, $Million, 2020-2031
  • Figure 78: Spain Carrier Screening Market, $Million, 2020-2031
  • Figure 79: Netherlands Carrier Screening Market, $Million, 2020-2031
  • Figure 80: Denmark Carrier Screening Market, $Million, 2020-2031
  • Figure 81: Belgium Carrier Screening Market, $Million, 2020-2031
  • Figure 82: Switzerland Carrier Screening Market, $Million, 2020-2031
  • Figure 83: Rest-of-Europe Carrier Screening Market, $Million, 2020-2031
  • Figure 84: Asia-Pacific Carrier Screening Market, $Million, 2020-2031
  • Figure 85: APAC Carrier Screening Market (by Country), $Million, 2020-2031
  • Figure 86: China Carrier Screening Market, $Million, 2020-2031
  • Figure 87: Japan Carrier Screening Market, $Million, 2020-2031
  • Figure 88: India Carrier Screening Market, $Million, 2020-2031
  • Figure 89: South Korea Carrier Screening Market, $Million, 2020-2031
  • Figure 90: Australia Carrier Screening Market, $Million, 2020-2031
  • Figure 91: Singapore Carrier Screening Market, $Million, 2020-2031
  • Figure 92: RoAPAC Carrier Screening Market, $Million, 2020-2031
  • Figure 93: Latin America Carrier Screening Market, $Million, 2020-2031
  • Figure 94: Latin America Carrier Screening Market (by Country), $Million, 2020-2031
  • Figure 95: Brazil Carrier Screening Market, $Million, 2020-2031
  • Figure 96: Mexico Carrier Screening Market, $Million, 2020-2031
  • Figure 97: RoLA Carrier Screening Market, $Million, 2020-2031
  • Figure 98: RoW Carrier Screening Market, $Million, 2020-2031
  • Figure 99: Middle East Carrier Screening Market, $Million, 2020-2031
  • Figure 100: Rest-of-Rest-of-the-World Carrier Screening Market, $Million, 2020-2031
  • Figure 101: Total Number of Companies Profiled
  • Figure 102: BGI Group: Product Portfolio
  • Figure 103: BGI Group: SWOT Analysis
  • Figure 104: CENTOGENE N.V.: Portfolio
  • Figure 105: CENTOGENE N.V.: Overall Financials, 2018-2020
  • Figure 106: CENTOGENE N.V.: Revenue (by Business Segment), 2018-2020
  • Figure 107: CENTOGENE N.V.: Revenue (by Region), 2018-2020
  • Figure 108: CENTOGENE N.V.: R&D Expenditure, 2018-2020
  • Figure 109: CENTOGENE N.V.: SWOT Analysis
  • Figure 110: Eurofins Scientific: Portfolio
  • Figure 111: Eurofins Scientific: Overall Financials, 2018-2020
  • Figure 112: Eurofins Scientific: Revenue (by Region), 2018-2020
  • Figure 113: Eurofins Scientific: SWOT Analysis
  • Figure 114: Fulgent Genetics, Inc.: Portfolio
  • Figure 115: Fulgent Genetics, Inc.: Overall Financials, 2018-2020
  • Figure 116: Fulgent Genetics, Inc.: Revenue (by Region), 2018-2020
  • Figure 117: Fulgent Genetics, Inc.: R&D Expenditure, 2018-2020
  • Figure 118: Fulgent Genetics, Inc.: SWOT Analysis
  • Figure 119: Gene by Gene, Ltd.: Portfolio
  • Figure 120: Gene by Gene, Ltd.: SWOT Analysis
  • Figure 121: Illumina, Inc.: Product Portfolio
  • Figure 122: Illumina, Inc.: Overall Financials, 2018-2020
  • Figure 123: Illumina, Inc.: Revenue (by Business Segment), 2018-2020
  • Figure 124: Illumina, Inc.: Revenue (by Region), 2018-2020
  • Figure 125: Illumina, Inc.: R&D Expenditure, 2018-2020
  • Figure 126: Illumina, Inc.: SWOT Analysis
  • Figure 127: Invitae Corporation: Portfolio
  • Figure 128: Invitae Corporation: Overall Financials, 2018-2020
  • Figure 129: Invitae Corporation: Revenue (by Business Segment), 2018-2020
  • Figure 130: Invitae Corporation: Revenue (by Region), 2018-2020
  • Figure 131: Invitae Corporation: R&D Expenditure, 2018-2020
  • Figure 132: Invitae Corporation: SWOT Analysis
  • Figure 133: Laboratory Corporation of America Holdings: Portfolio
  • Figure 134: Laboratory Corporation of America Holdings: Overall Financials, 2018-2020
  • Figure 135: Laboratory Corporation of America Holdings: Revenue (by Segment), 2018-2020
  • Figure 136: Laboratory Corporation of America Holdings: Revenue (by Region), 2018-2020
  • Figure 137: Laboratory Corporation of America Holdings: SWOT Analysis
  • Figure 138: Myriad Genetics, Inc.: Portfolio
  • Figure 139: Myriad Genetics, Inc.: Overall Financials, 2018-2020
  • Figure 140: Myriad Genetics, Inc.: Revenue (by Business Segment), 2018-2020
  • Figure 141: Myriad Genetics, Inc.: Revenue (by Region), 2018-2020
  • Figure 142: Myriad Genetics, Inc.: R&D Expenditure, 2018-2020
  • Figure 143: Myriad Genetics, Inc.: SWOT Analysis
  • Figure 144: Natera, Inc.: Portfolio
  • Figure 145: Natera, Inc.: Overall Financials, 2018-2020
  • Figure 146: Natera, Inc.: Revenue (by Business Segment), 2018-2020
  • Figure 147: Natera, Inc.: Revenue (by Region), 2018-2020
  • Figure 148: Natera, Inc.: R&D Expenditure, 2018-2020
  • Figure 149: Natera, Inc.: SWOT Analysis
  • Figure 150: OPKO Health: Portfolio
  • Figure 151: OPKO Health: Overall Financials, 2018-2020
  • Figure 152: OPKO Health: Revenue (by Business Segment), 2018-2020
  • Figure 153: OPKO Health: Revenue (by Region), 2018-2020
  • Figure 154: OPKO Health: R&D Expenditure, 2018-2020
  • Figure 155: OPKO Health: SWOT Analysis
  • Figure 156: Quest Diagnostics Incorporated: Portfolio
  • Figure 157: Quest Diagnostics Incorporated: Overall Financials, 2018-2020
  • Figure 158: Quest Diagnostics Incorporated: Revenue (by Segment), 2018-2020
  • Figure 159: Quest Diagnostics Incorporated: SWOT Analysis
  • Figure 160: Sema4: Portfolio
  • Figure 161: Sema4: SWOT Analysis
  • Figure 162: Thermo Fisher Scientific Inc.: Product Portfolio
  • Figure 163: Thermo Fisher Scientific Inc.: Overall Financials, 2018-2020
  • Figure 164: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), 2018-2020
  • Figure 165: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020
  • Figure 166: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
  • Figure 167: Thermo Fisher Scientific Inc.: SWOT Analysis
  • Figure 168: Yourgene Health Plc: Portfolio
  • Figure 169: Yourgene Health plc: Overall Financials, 2018-2020
  • Figure 170: Yourgene Health Plc: Revenue (by Business Segment), 2019-2020
  • Figure 171: Yourgene Health Plc: Revenue (by Region), 2018-2020
  • Figure 172: Yourgene Health Plc: R&D Expenditure, 2018-2020
  • Figure 173: Yourgene Health Plc: SWOT Analysis

List of Tables

  • Table 1: Classification of Medical Device
  • Table 2: Likert Scale
  • Table 3: Impact Analysis of Market Drivers
  • Table 4: Impact Analysis of Market Restraints
  • Table 5: Companies Providing Expanded Carrier Screening
  • Table 6: Companies Providing Customized Panel Testing
  • Table 7: Companies Offering Predesigned Panel Testing
  • Table 8: Companies Offering Fragile X Syndrome Tests
  • Table 9: Companies Offering Cystic Fibrosis Tests
  • Table 10: Companies Offering Thalassemia Tests
  • Table 11: Companies Offering Huntington's Disease Tests
  • Table 12: Companies Offering Sickle Cell Anemia Test
  • Table 13: Companies Offering Hemophilia Test
  • Table 14: North America: Market Dynamics
  • Table 15: Europe: Market Dynamics
  • Table 16: APAC: Market Dynamics
  • Table 17: Latin America: Market Dynamics

“Global Carrier Screening Market to Reach $4,479.0 Million by 2031.”

Market Report Coverage - Carrier Screening

Market Segmentation

  • Type (Expanded Carrier Screening and Targeted Carrier Screening)
  • Product (In Vitro Diagnostics And Laboratory Developed Tests)
  • Carrier Screening Type (Prenatal Carrier Screening And Preconception Carrier Screening)
  • Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Microarray, And Other Technologies)
  • Indication (Fragile X Syndrome, Cystic Fibrosis, Spinal Muscular Atrophy, Down's Syndrome, Thalassemia, Tay-Sachs Disease, Huntington's Disease, Sickle Cell Anemia, Hemophilia, and Other Indications)

Regional Segmentation

  • North America: U.S., Canada
  • Europe: Germany, France, U.K, Italy, Spain, Netherlands, Denmark, Belgium, Switzerland and Rest-of-Europe
  • Asia-Pacific: China, Japan, India, South Korea, Australia, Singapore, Rest-of-Asia-Pacific
  • Latin America: Brazil, Mexico, Rest-of-Latin America
  • Rest-of-the-World

Market Growth Drivers

  • Decreasing Cost of Sequencing
  • Rising Emphasis on Early Detection and Prevention of Complex Genetic Disorders
  • Increasing Maternal Age Leading to Pregnancy Complications
  • Rising Funding and Innovation in the carrier Screening Ecosystem

Market Challenges

  • Regulatory Challenges in the Field of Carrier Screening
  • Lack of High Complexity Testing Centers
  • Existing Diagnostic Confidence on Conventional Screening Methods

Market Opportunities

  • Massive Scope for Adoption of Carrier Screening in Developing Nations

Key Companies Profiled

BGI Group, CENTOGENE N.V., Eurofins Scientific, Fulgent Genetics, Inc., Gene by Gene, Ltd., Illumina, Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Myriad Genetics, Inc., Natera, Inc., OPKO Health, Quest Diagnostics Incorporated, Sema4, Thermo Fisher Scientific Inc., Yourgene Health Plc.

Key Questions Answered in this Report:

  • How is carrier screening revolutionizing the field of reproductive health?
  • What are the major market drivers, challenges, and opportunities in the global carrier screening market?
  • What are the underlying structures resulting in the emerging trends within the global carrier screening market?
  • How is the COVID-19 pandemic impacting the global carrier screening ecosystem??
  • What are the key development strategies that the major players are implementing in order to sustain themselves in the competitive market?
  • What are the key regulatory implications in developed and developing regions pertaining to the use of carrier screening?
  • What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?
  • How is each market segment expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment? Following are the segments:
    • Type (expanded carrier screening and targeted carrier screening)
    • Product (in vitro diagnostics and laboratory developed tests)
    • Carrier Screening Type (prenatal carrier screening and preconception carrier screening)
    • Technology (next-generation sequencing, polymerase chain reaction, microarray, and other technologies)
    • Indication (fragile X syndrome, cystic fibrosis, spinal muscular atrophy, Down's Syndrome, thalassemia, Tay-Sachs Disease, Huntington's Disease, sickle cell anemia, hemophilia, and other indications)
    • Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
  • What are the growth opportunities for the carrier screening companies in the region of their operation?
  • Who are the leading players with significant offerings in the global carrier screening market?
  • Which companies are anticipated to be highly disruptive in the future, and why?

Market Overview

The growth of the carrier screening market is expected to be driven by the decrease in the cost of sequencing, rising emphasis on early detection and prevention of complex genetic disorders, and increasing maternal age leading to pregnancy complications. However, there are significant challenges restraining the market growth, such as the regulatory challenges in the field of carrier screening, and the lack of high complexity testing centers. Carrier screening is a hereditary test that gives information about whether a person carries a gene for certain genetic disorders. It is performed before or during pregnancy times. Carrier screening allows a person to find out the chances of having a child with a genetic disorder. Carrier screening involves testing blood, saliva, or tissue extracted from inside the cheeks. In cases of genetic disorders, a person should have two affected genes to have the disorder. A person who is a carrier has only one gene for a disorder and usually does not have symptoms or have only mild symptoms. The current market for carrier screening is majorly dominated by manufacturers and service providers such as BGI Group, CENTOGENE N.V., Eurofins Scientific, Fulgent Genetics, Inc., Gene by Gene, Ltd., Illumina, Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Myriad Genetics, Inc., Natera, Inc., OPKO Health, Quest Diagnostics Incorporated, Sema4, Thermo Fisher Scientific Inc., and Yourgene Health Plc.

The global carrier screening market is projected to reach $4,479.0 million by 2031, growing from $1,187.4 million in 2020, at a CAGR of 12.67% during the forecast period 2021-2031.

The carrier screening market is an emerging market with huge growth potential. Recent technological advancements are facilitating the adoption of the technology at a rapid pace. Carrier screening are genetic tests that are used for determining if a person is a potential carrier of genetic disorders such as cystic fibrosis (CF), Down's syndrome, Fragile X syndrome, sickle cell anemia, and spinal muscular atrophy (SMA). Carrier screening tests are extensively used by couples considering becoming pregnant to determine the risks of passing genetic anomalies to the child. This study aims at deciphering the potential of carrier screening and its larger role in bolstering the current era of precision medicine in the field of reproductive health.

Competitive Landscape

The growth of this market can be majorly attributed to the presence of well-established guidelines regarding carrier screening, presence of established companies undertaking key business strategies, decrease in the cost of sequencing, rising emphasis on early detection and prevention of complex genetic disorders, and increasing maternal age leading to pregnancy complications, among others. Further, increasing focus on research pertaining to carrier screening such as targeted carrier screening in spinal muscle atrophy and emerging application of preconcecption carrier screening is also expected to support the growth of the carrier screening market during the forecast period, 2021-2031.

The growth of other technologies, such as next-generation sequencing and PCR can be attributed to the increased clinical research to understand the involvement of molecular pathology in the diagnosis and prognosis of genetic disorders. Based on region, North America holds the largest share in the market, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. However, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period 2021-2031.

Table of Contents

1 Market

  • 1.1 Product Definition
    • 1.1.1 Inclusion and Exclusion
  • 1.2 Market Scope
    • 1.2.1 Scope of the Study
    • 1.2.2 Key Questions Answered in the Report
  • 1.3 Research Methodology
    • 1.3.1 Global Carrier Screening Market: Research Methodology
    • 1.3.2 Data Sources
      • 1.3.2.1 Primary Data Sources
      • 1.3.2.2 Secondary Data Sources
    • 1.3.3 Market Estimation Model
    • 1.3.4 Criteria for Company Profiling
  • 1.4 Market Overview
    • 1.4.1 Emerging Applications of Carrier Screening
    • 1.4.2 Appropriate Use Criteria
      • 1.4.2.1 Carrier Screening for Familial Disease
        • 1.4.2.1.1 Fragile X Syndrome (FXS)
      • 1.4.2.2 Carrier Screening for Common and Ethnic Genetic Diseases
        • 1.4.2.2.1 Cystic Fibrosis
        • 1.4.2.2.2 Spinal Muscular Atrophy
        • 1.4.2.2.3 Hemoglobinopathy
        • 1.4.2.2.4 Ashkenazi Jewish Carrier Screening
      • 1.4.2.3 Other Ethnicities
    • 1.4.3 Market Footprint and Growth Potential
    • 1.4.4 Disruption in Global Carrier Screening Market Due to COVID-19
    • 1.4.5 Navigating Crisis Recovery and Looking to the Future

2 Industry Analysis

  • 2.1 Overview
  • 2.2 Legal Requirements and Framework in the U.S.
    • 2.2.1 U.S. Food and Drug Administration (FDA)
    • 2.2.2 American College of Medical Genetics and Genomics (ACMG)
    • 2.2.3 American College of Obstetricians and Gynecologists
  • 2.3 Legal Requirements and Framework in Europe
  • 2.4 Legal Requirements and Framework in Asia-Pacific
    • 2.4.1 China
    • 2.4.2 Japan
  • 2.5 Reimbursement Analysis

3 Market Dynamics

  • 3.1 Overview
  • 3.2 Impact Analysis
  • 3.3 Market Drivers
    • 3.3.1 Decreasing Cost of Sequencing
    • 3.3.2 Rising Emphasis on Early Detection and Prevention of Complex Genetic Disorders
    • 3.3.3 Increasing Maternal Age Leading to Pregnancy Complications
    • 3.3.4 Rising Funding and Innovation in the Carrier Screening Ecosystem
  • 3.4 Market Restraints
    • 3.4.1 Regulatory Challenges in the Field of Carrier Screening
    • 3.4.2 Lack of High Complexity Testing Centers
    • 3.4.3 Existing Diagnostic Confidence on Conventional Screening Methods
  • 3.5 Market Opportunities
    • 3.5.1 Massive Scope for Adoption of Carrier Screening in Developing Nations

4 Competitive Landscape

  • 4.1 Overview
  • 4.2 Product Launches
  • 4.3 Synergistic Activities
  • 4.4 Acquisitions
  • 4.5 Product Approvals and Fundings
  • 4.6 Market Share Analysis, 2019-2020
  • 4.7 Growth Share Analysis

5 Type, $Million, 2020 - 2031

  • 5.1 Overview
  • 5.2 Expanded Carrier Screening
    • 5.2.1 Customized Panel Testing
    • 5.2.2 Predesigned Panel Testing
  • 5.3 Targeted Carrier Screening

6 Product, $Million, 2020 - 2031

  • 6.1 Overview
  • 6.2 In Vitro Diagnostics (IVD)
  • 6.3 Laboratory Developed Tests (LDT)

7 Carrier Screening Type, $Million, 2020-2031

  • 7.1 Overview
  • 7.2 Prenatal Carrier Screening
    • 7.2.1 IVDs
    • 7.2.2 LDTs
  • 7.3 Preconception Carrier Screening
    • 7.3.1 IVDs
    • 7.3.2 LDTs

8 Technology, $Million, 2020 - 2031

  • 8.1 Overview
  • 8.2 Next-Generation Sequencing (NGS)
  • 8.3 Polymerase Chain Reaction (PCR)
    • 8.3.1 Real-Time Polymerase Chain Reaction (RT-PCR)
    • 8.3.2 Digital PCR (dPCR)
  • 8.4 Microarray
  • 8.5 Other Technologies

9 Indication, $Million, 2020 - 2031

  • 9.1 Overview
  • 9.2 Fragile X syndrome
  • 9.3 Cystic Fibrosis
  • 9.4 Spinal Muscular Atrophy
  • 9.5 Down's Syndrome
  • 9.6 Thalassemia
  • 9.7 Tay-Sachs Disease
  • 9.8 Huntington's Disease
  • 9.9 Sickle Cell Anemia
  • 9.1 Hemophilia
  • 9.11 Other Indication

10 Region, $Million, 2020-2031

  • 10.1 Overview
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 France
    • 10.3.3 U.K.
    • 10.3.4 Italy
    • 10.3.5 Spain
    • 10.3.6 Netherlands
    • 10.3.7 Denmark
    • 10.3.8 Belgium
    • 10.3.9 Switzerland
    • 10.3.10 Rest-of-Europe
  • 10.4 Asia-Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 South Korea
    • 10.4.5 Australia
    • 10.4.6 Singapore
    • 10.4.7 Rest-of-Asia-Pacific (RoAPAC)
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Rest-of-Latin America (RoLA)
  • 10.6 Rest-of-the-World
    • 10.6.1 Middle East
    • 10.6.2 Rest-of-Rest-of-the-World

11 Company Profiles

  • 11.1 Overview
  • 11.2 BGI Group
    • 11.2.1 Company Overview
    • 11.2.2 Role of BGI Group in the Global Carrier Screening Market
    • 11.2.3 SWOT Analysis
  • 11.3 CENTOGENE N.V.
    • 11.3.1 Company Overview
    • 11.3.2 Role of CENTOGENE N.V. in the Global Carrier Screening Market
    • 11.3.3 Financials
    • 11.3.4 Key Insights About Financial Health of the Company
    • 11.3.5 SWOT Analysis
  • 11.4 Eurofins Scientific
    • 11.4.1 Company Overview
    • 11.4.2 Role of Eurofins Scientific in the Global Carrier Screening Market
    • 11.4.3 Financials
    • 11.4.4 SWOT Analysis
  • 11.5 Fulgent Genetics, Inc.
    • 11.5.1 Company Overview
    • 11.5.2 Role of Fulgent Genetics, Inc. in the Global Carrier Screening Market
    • 11.5.3 Financials
    • 11.5.4 Key Insights About Financial Health of the Company
    • 11.5.5 SWOT Analysis
  • 11.6 Gene by Gene, Ltd.
    • 11.6.1 Company Overview
    • 11.6.2 Role of Gene by Gene, Ltd. in the Global Carrier Screening Market
    • 11.6.3 SWOT Analysis
  • 11.7 Illumina, Inc.
    • 11.7.1 Company Overview
    • 11.7.2 Role of Illumina, Inc. in the Global Carrier Screening Market
    • 11.7.3 Financials
    • 11.7.4 Key Insights About Financial Health of the Company
    • 11.7.5 SWOT Analysis
  • 11.8 Invitae Corporation
    • 11.8.1 Company Overview
    • 11.8.2 Role of Invitae Corporation in the Global Carrier Screening Market
    • 11.8.3 Financials
    • 11.8.4 Key Insights About Financial Health of the Company
    • 11.8.5 SWOT Analysis
  • 11.9 Laboratory Corporation of America Holdings
    • 11.9.1 Company Overview
    • 11.9.2 Role of Laboratory Corporation of America Holdings in the Global Carrier Screening Market
    • 11.9.3 Financials
    • 11.9.2 SWOT Analysis
  • 11.1 Myriad Genetics, Inc.
    • 11.10.1 Company Overview
    • 11.10.2 Role of Myriad Genetics, Inc. in the Global Carrier Screening Market
    • 11.10.3 Financials
    • 11.10.4 Key Insights About Financial Health of the Company
    • 11.10.5 SWOT Analysis
  • 11.11 Natera, Inc.
    • 11.11.1 Company Overview
    • 11.11.2 Role of Natera, Inc. in the Global Carrier Screening Market
    • 11.11.3 Financials
    • 11.11.4 Key Insights About Financial Health of the Company
    • 11.11.5 SWOT Analysis
  • 11.12 OPKO Health
    • 11.12.1 Company Overview
    • 11.12.2 Role of OPKO Health in the Global Carrier Screening Market
    • 11.12.3 Financials
    • 11.12.4 Key Insights About Financial Health of the Company
    • 11.12.5 SWOT Analysis
  • 11.13 Quest Diagnostics Incorporated
    • 11.13.1 Company Overview
    • 11.13.2 Role of Quest Diagnostics Incorporated in the Global Carrier Screening Market
    • 11.13.3 Financials
    • 11.13.4 SWOT Analysis
  • 11.14 Sema4
    • 11.14.1 Company Overview
    • 11.14.2 Role of Sema4 in the Global Carrier Screening Market
    • 11.14.3 SWOT Analysis
  • 11.15 Thermo Fisher Scientific Inc.
    • 11.15.1 Company Overview
    • 11.15.2 Role of Thermo Fisher Scientific Inc. in the Global Carrier Screening Market
    • 11.15.3 Financials
    • 11.15.4 Key Insights About Financial Health of the Company
    • 11.15.5 SWOT Analysis
  • 11.16 Yourgene Health Plc
    • 11.16.1 Company Overview
    • 11.16.2 Role of Yourgene Health Plc in the Global Carrier Screening Market
    • 11.16.3 Financials
    • 11.16.4 Key Insights About Financial Health of the Company
    • 11.16.5 SWOT Analysis
Back to Top
전화 문의
F A Q